Retraction to: Retraction Note to: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells (Tumor Biol., (2012), 33, (1053-1058), DOI 10.1007/s13277-012-0339-x);Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Tumor Biology

Volumn 33, Issue 4, 2012, Pages 1053-1058

  Takai, Noriyuki ^a   Ueda, Tami ^a   Kira, Naoko ^a   Ishii, Terukazu ^a   Yoshida, Toshie ^a   Koga, Satoko ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Calcium calmodulin dependent kinase; Cell cycle; Choriocarcinoma; KN 93

Indexed keywords

BENZYLAMINE DERIVATIVE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CASPASE 3; CYCLIN A; CYCLIN D1; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHORIOCARCINOMA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BENZYLAMINES; BLOTTING, WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHORIOCARCINOMA; CYCLIN A; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; SULFONAMIDES;

EID: 85027942817     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3666-x     Document Type: Erratum

References (22)

1. Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experi-ence. Int J Gynecol Cancer. 1997;7:27–33.
2. Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple che-motherapy in the management of high-risk gestational trophoblas-tic tumors. Gynecol Oncol. 1984;19:173–81.
3. Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.
4. Satsu H, Manabe M, Shimizu M. Activation of Ca2+/calmodulin-dependent protein kinase II is involved in hyperosmotic induction of the human taurine transporter. FEBS Lett. 2004;569:123–8.
5. Rodriguez-Mora O, LaHair M, McCubrey J., Franklin R. Calcium/ calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005;65:5408–16.
6. 2+/calmodulin-dependent protein kinase. J Biol Chem. 1998;273:21473–81.
7. Tokumitsu H, Brickey D, Glod J, Hidaka H, Sikela J, Soderling T. Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase. J Biol Chem. 1994;269:28640–7.
8. Racioppi L, Means AR. Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an an-cient traveler. Trends Immunol. 2008;29:600–7.
9. Tombes RM, Grant S, Westin EH, Krystal G. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995;6:1063–70.
10. Kawamura K, Grabowski D, Krivacic K, Hidaka H, Ganapathi R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium–calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phos-phorylation. Biochem Pharmacol. 1996;52:1903–9.
11. 2+ /calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine con-t ent s i n PC12h cel l s. Bi ochem Bi ophys Res Commun. 1991;181:968–75.
12. Kahl C, Means A. Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. J Biol Chem. 2004;279:15411–9.
13. Shang S, Takai N, Nishida M, Miyazaki T, Nasu K, Miyakawa I. CaMKIV expression is associated with clinical stage and PCNA labeling index in endometrial carcinoma. Int J Mol Med. 2003;11:181–6.
14. Takai N, Ueda T, Nasu K, Yamashita S, Toyofuku M, Narahara H. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas. Cancer Lett. 2009;277:235–43.
15. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth act i vi t y i n endomet r i al cancer cel l s. Cl i n Cancer Res. 2004;10:1141–9.
16. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endo-metrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.
17. Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.
18. Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human mel-anoma cells. Cancer Res. 2001;61:6437–44.
19. Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.
20. Annu Rev Pharmacol Toxicol. 1999;39:295–312.
21. Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551– 5.
22. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological var-iables. J Cancer Res Clin Oncol. 2002;128:307–12.